ReviewAlzheimer's & dementia (New York, N. Y.)2018
Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience.
Review in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Identifying gait characteristics associated with freezing of gait in Parkinson's disease: An analysis of on and off medication states.Gait & posture · 2025Article
- Practice effects persist over two decades of cognitive testing: Implications for longitudinal research.medRxiv : the preprint server for health sciences · 2025Article
- Dual-Task Performance and Brain Morphologic Characteristics in Parkinson's Disease.Neuro-degenerative diseases · 2024Article
- Classifying Alzheimer's Disease Neuropathology Using Clinical and MRI Measurements.Journal of Alzheimer's disease : JAD · 2024Article
- Disparities in structural brain imaging in older adults from rural communities in Southern Nevada.Frontiers in aging neuroscience · 2024Article
- Cognitive aging in rural communities: preliminary memory characterization of a community cohort from Southern Nevada.Frontiers in dementia · 2023Article
- Effects of dose change on the success of clinical trials.Contemporary clinical trials communications · 2022Article
- A Novel Way of Measuring Dual-Task Interference: The Reliability and Construct Validity of the Dual-Task Effect Battery in Neurodegenerative Disease.Neurorehabilitation and neural repair · 2022Article
- The roles of executive functioning, simple attention, and medial temporal lobes in early learning, late learning, and delayed recall.Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition · 2022Article
- Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults.The journal of prevention of Alzheimer's disease · 2022Article
- Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment.Frontiers in psychiatry · 2022Article
- Study on the Prediction Method of Long-term Benign and Malignant Pulmonary Lesions Based on LSTM.Frontiers in bioengineering and biotechnology · 2022Article
- A novel framework to estimate cognitive impairment via finger interaction with digital devices.Brain communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The development of disease-modifying therapies for Alzheimer's disease is an urgent public health emergency. Recent failures have highlighted the significant challenges faced by drug-development programs. Longitudinal cohort studies are ideal for promoting understanding of this multifactorial, slowly progressive disease. In this section of the special edition, we review several important lessons from longitudinal cohort studies which should be considered in disease-modifying therapy development. In the final section, we introduce the clinical cohort of the Center for Neurodegeneration and Translational Neuroscience. This newly established longitudinal study aims to provide new insights into the neuroimaging and biological marker (biomarkers) correlates of cognitive decline in early Alzheimer's disease and Parkinson's disease (PD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.